Alcon and Novartis have finally agreed on the terms by which Novartis will buy the Alcon shares it does not already own. The total consideration is valued at $168 per Alcon share, made up of Novartis shares and, if necessary, cash to make up the difference. The exact ratio is ...
Buying a membership today will give you:
To continue reading this article register now.